{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:31:42Z","timestamp":1755217902625,"version":"3.43.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancessurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Surgery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.yasu.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:41:43Z","timestamp":1749771703000},"page":"161-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral Anticoagulant Management for Peripheral Vascular Disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Bianca","family":"Mulaney-Topkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.yasu.2025.05.003_bib1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib2","first-page":"E67","article-title":"The Current U.S. prevalence of peripheral arterial disease","volume":"20","author":"Yost","year":"2023","journal-title":"Vascular Disease Management"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population","volume":"60","author":"Nehler","year":"2014","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lpm.2018.01.012","article-title":"\u00c9pid\u00e9miologie de l\u2019art\u00e9riopathie des membres inf\u00e9rieurs","volume":"47","author":"Aboyans","year":"2018","journal-title":"Presse Med"},{"key":"10.1016\/j.yasu.2025.05.003_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/VHRM.S209241","article-title":"The burden of critical limb ischemia: a review of recent literature","volume":"15","author":"Duff","year":"2019","journal-title":"VHRM"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib6","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Abu Dabrh","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.yasu.2025.05.003_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006566","article-title":"Outcomes among patients with end-stage kidney disease and chronic limb-threatening ischemia: a population-based Cohort Study","author":"Shah","year":"2024","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejvs.2020.09.018","article-title":"Mortality in octogenarians with chronic limb threatening ischaemia after revascularisation or conservative therapy alone","volume":"61","author":"W\u00fcbbeke","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"24","key":"10.1016\/j.yasu.2025.05.003_bib9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib10","first-page":"609S","article-title":"Antithrombotic therapy in peripheral arterial occlusive disease","volume":"126","author":"Clagett","year":"2004","journal-title":"Chest (Am Coll Chest Physicians)"},{"issue":"18","key":"10.1016\/j.yasu.2025.05.003_bib11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.yasu.2025.05.003_bib12","first-page":"1345","article-title":"Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains","volume":"126","author":"Subherwal","year":"2012","journal-title":"Circulation (New York, N Y)"},{"key":"10.1016\/j.yasu.2025.05.003_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2021.100113","article-title":"Peripheral artery disease in Germany (2009\u20132018): prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy \u2013 a population-based study","volume":"5","author":"Rammos","year":"2021","journal-title":"Lancet Regional Health - Europe"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib14","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jvs.2023.08.093","article-title":"Evidence for underprescription of guideline-recommended cardiovascular medications to adults with peripheral artery disease: a systematic review and meta-analysis","volume":"78","author":"Paquet","year":"2023","journal-title":"J Vasc Surg"},{"issue":"11","key":"10.1016\/j.yasu.2025.05.003_bib15","first-page":"1319","article-title":"Medical management of peripheral arterial disease: bridging the \u201cgap\u201d","volume":"126","author":"Owens","year":"2012","journal-title":"Circulation (New York, N Y)"},{"issue":"S1","key":"10.1016\/j.yasu.2025.05.003_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27258","article-title":"The impact of sex on platelet responses to aspirin in patients with peripheral artery disease","volume":"99","author":"Suarez Ferreira","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.yasu.2025.05.003_bib17","series-title":"StatPearls","article-title":"Physiology, clotting mechanism","author":"Garmo","year":"2024"},{"issue":"6618","key":"10.1016\/j.yasu.2025.05.003_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bmj.296.6618.320","article-title":"Secondary prevention of vascular disease by prolonged antiplatelet treatment","volume":"296","year":"1988","journal-title":"BMJ"},{"issue":"9678","key":"10.1016\/j.yasu.2025.05.003_bib19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Trialists\u2019 Collaboration","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.yasu.2025.05.003_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001272.pub2","article-title":"Antiplatelet agents for intermittent claudication. Cochrane Vascular Group","author":"Wong","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.yasu.2025.05.003_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"issue":"10235","key":"10.1016\/j.yasu.2025.05.003_bib22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"issue":"9038","key":"10.1016\/j.yasu.2025.05.003_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"10235","key":"10.1016\/j.yasu.2025.05.003_bib24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Supplemental Table 3 in Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.yasu.2025.05.003_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor\u2019s choice \u2013 European society for vascular surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"issue":"8426","key":"10.1016\/j.yasu.2025.05.003_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(85)91144-4","article-title":"Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease","volume":"325","author":"Hess","year":"1985","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.yasu.2025.05.003_bib29","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","article-title":"Effect of dipyridamole plus aspirin on hemodialysis graft patency","volume":"360","author":"Dixon","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM198401263100401","article-title":"Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations","volume":"310","author":"Chesebro","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yasu.2025.05.003_bib31","first-page":"207","article-title":"Treatment of claudication with dipyridamole and aspirin","volume":"14","author":"Libretti","year":"1986","journal-title":"Monogr Atheroscler"},{"key":"10.1016\/j.yasu.2025.05.003_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001820.pub3","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Stroke Group Cochrane Database of Systematic Reviews","author":"De Schryver","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib33","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Vascular Group","volume":"2023","author":"Forster","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.yasu.2025.05.003_bib34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.yasu.2025.05.003_bib35","first-page":"997","volume":"133","author":"Bonaca","year":"2016","journal-title":"Circulation (New York, N Y)"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.yasu.2025.05.003_bib37","series-title":"StatPearls","article-title":"Cangrelor","author":"Awosika","year":"2024"},{"issue":"04","key":"10.1016\/j.yasu.2025.05.003_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0030-1267856","article-title":"Review of currently available GP IIb\/IIIa inhibitors and their role in peripheral vascular Interventions","volume":"27","author":"Stangl","year":"2010","journal-title":"Semin Interv Radiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ehj.2013.04.002","article-title":"Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions","volume":"66","author":"Nassar","year":"2014","journal-title":"Egypt Heart J"},{"key":"10.1016\/j.yasu.2025.05.003_bib40","series-title":"StatPearls","article-title":"Warfarin","author":"Patel","year":"2024"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib41","first-page":"242","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation (New York, N Y)"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib42","first-page":"65","article-title":"Direct oral anticoagulants as the first choice of anticoagulation for patients with peripheral artery disease to prevent adverse vascular events: a systematic review and meta-analysis","volume":"10","author":"Pomozi","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"9921","key":"10.1016\/j.yasu.2025.05.003_bib43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"10117","key":"10.1016\/j.yasu.2025.05.003_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.yasu.2025.05.003_bib45","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemostasis"},{"issue":"5","key":"10.1016\/j.yasu.2025.05.003_bib48","article-title":"Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Vascular Group","volume":"2014","author":"Cosmi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejvs.2004.11.011","article-title":"Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia\u2014a randomised placebo-controlled double blind multicentre trial","volume":"29","author":"Jiveg\u00e5rd","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9","key":"10.1016\/j.yasu.2025.05.003_bib50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial indexa randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"oct16 2","key":"10.1016\/j.yasu.2025.05.003_bib51","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.yasu.2025.05.003_bib52","first-page":"2053","article-title":"Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation (New York, N Y)"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2006.03.011","article-title":"Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review","volume":"189","author":"Heald","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yasu.2025.05.003_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8295054","article-title":"Burden of coronary artery disease and peripheral artery disease: a literature review","volume":"2019","author":"Bauersachs","year":"2019","journal-title":"Cardiovascular Therapeutics"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5694\/j.1326-5377.2004.tb06206.x","article-title":"Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications","volume":"181","author":"Norman","year":"2004","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2008","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2\u00b0P-TIMI 50 trial","volume":"25","author":"Qamar","year":"2020","journal-title":"Vasc Med"},{"issue":"14","key":"10.1016\/j.yasu.2025.05.003_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yasu.2025.05.003_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.4390","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","author":"Kaplovitch","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.yasu.2025.05.003_bib60","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/bjs.9127","article-title":"Meta-analysis of contemporary short- and long-term mortality rates in patients diagnosed with critical leg ischaemia","volume":"100","author":"Rollins","year":"2013","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejvs.2017.11.006","article-title":"Outcomes of patients with critical limb ischaemia in the EUCLID Trial","volume":"55","author":"Norgren","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J Vasc Surg"},{"issue":"9","key":"10.1016\/j.yasu.2025.05.003_bib63","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejvs.2016.12.014","article-title":"Editor\u2019s choice \u2013 dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia","volume":"53","author":"Thott","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"23","key":"10.1016\/j.yasu.2025.05.003_bib65","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD Trial","volume":"25","author":"Moll","year":"2018","journal-title":"J Endovasc Ther"},{"issue":"24","key":"10.1016\/j.yasu.2025.05.003_bib67","first-page":"1919","article-title":"Rivaroxaban plus aspirin versus aspirin alone after endovascular revascularization for symptomatic PAD: insights from VOYAGER PAD","volume":"148","author":"Rymer","year":"2023","journal-title":"Circulation (New York, N Y)"},{"issue":"23","key":"10.1016\/j.yasu.2025.05.003_bib68","first-page":"2219","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation (New York, N Y)"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejvs.2020.03.010","article-title":"Antiplatelet and anticoagulant use in randomised trials of patients undergoing endovascular intervention for peripheral arterial disease: systematic review and narrative synthesis","volume":"60","author":"Qureshi","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"Megaly","year":"2019","journal-title":"Vasc Med"},{"issue":"10","key":"10.1016\/j.yasu.2025.05.003_bib71","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation (New York, N Y)"},{"issue":"23","key":"10.1016\/j.yasu.2025.05.003_bib72","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.yasu.2025.05.003_bib73","first-page":"1104","article-title":"Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD Trial","volume":"144","author":"Debus","year":"2021","journal-title":"Circulation (New York, N Y)"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jvs.2012.01.004","article-title":"Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients","volume":"56","author":"Monaco","year":"2012","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib75","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2024.03.349","article-title":"Optimal anticoagulation and antiplatelet therapy in prosthetic infrapopliteal bypass","volume":"79","author":"Rakestraw","year":"2024","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib77","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0741-5214(98)70130-2","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg"},{"issue":"9201","key":"10.1016\/j.yasu.2025.05.003_bib78","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1067\/mva.2002.121847","article-title":"Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study","volume":"35","author":"Johnson","year":"2002","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejvs.2016.03.026","article-title":"Role of vitamin k antagonists in the prevention of thrombotic bypass occlusion after infrainguinal venous bypass","volume":"52","author":"G\u00e1ndara","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejvs.2021.10.026","article-title":"Revascularisation for symptomatic peripheral artery disease: external applicability of the VOYAGER PAD Trial","volume":"63","author":"S\u00f8gaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9","key":"10.1016\/j.yasu.2025.05.003_bib82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.repc.2020.02.012","article-title":"Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome","volume":"39","author":"Faria","year":"2020","journal-title":"Rev Port Cardiol"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib83","first-page":"583","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation (New York, N Y)"},{"issue":"5","key":"10.1016\/j.yasu.2025.05.003_bib84","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.yasu.2025.05.003_bib85","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib86","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jvs.2009.04.011","article-title":"Patients with peripheral arterial disease in the CHARISMA Trial","volume":"49","author":"Cacoub","year":"2009","journal-title":"J Vasc Surg"},{"issue":"10093","key":"10.1016\/j.yasu.2025.05.003_bib87","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib88","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib89","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and longterm antithrombotic therapy in older adults","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.yasu.2025.05.003_bib90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jcin.2021.01.040","article-title":"Antithrombotic management of elderly patients with coronary artery disease","volume":"14","author":"Capranzano","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib91","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ehjcvp\/pvz032","article-title":"Anti-thrombotic strategies in elderly patients receiving platelet inhibitors","volume":"6","author":"Sch\u00e4fer","year":"2020","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib92","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2215\/CJN.05600515","article-title":"CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia","volume":"11","author":"L\u00fcders","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.yasu.2025.05.003_bib93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.atherosclerosis.2019.12.016","article-title":"Chronic kidney disease and outcomes of lower extremity revascularization for peripheral artery disease","volume":"297","author":"Smilowitz","year":"2020","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.yasu.2025.05.003_bib94","first-page":"2649","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation (New York, N Y)"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib95","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ndt\/gfz040","article-title":"Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update","volume":"34","author":"Burlacu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"10.1016\/j.yasu.2025.05.003_bib96","first-page":"1582","article-title":"P2Y12 -ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes: review of the current evidence","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation (New York, N Y)"},{"issue":"suppl_3","key":"10.1016\/j.yasu.2025.05.003_bib97","doi-asserted-by":"crossref","first-page":"iii276","DOI":"10.1093\/ndt\/gfv181.03","article-title":"FP610 platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study","volume":"30","author":"Jeong","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.yasu.2025.05.003_bib98","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"J Thromb Haemostasis"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib99","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/gfy031","article-title":"A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation","volume":"34","author":"Feldberg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib100","first-page":"240","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation (New York, N Y)"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jvs.2018.09.062","article-title":"Hypercoagulability predicts worse outcomes in young patients undergoing lower extremity revascularization","volume":"70","author":"Torrealba","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.yasu.2025.05.003_bib102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2023.08.006","article-title":"Factor V Leiden, prothrombin, MTHFR, and PAI-1 gene polymorphisms in patients with arterial disease: a comprehensive systematic-review and meta-analysis","volume":"230","author":"Valeriani","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.yasu.2025.05.003_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib104","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.semarthrit.2020.08.012","article-title":"Antiphospholipid antibodies and lower extremity peripheral artery disease: a systematic review and meta-analysis","volume":"50","author":"Merashli","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.yasu.2025.05.003_bib106","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jvs.2018.12.036","article-title":"Association of opioid use and peripheral artery disease","volume":"70","author":"Itoga","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.yasu.2025.05.003_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107665","article-title":"The opioid-P2Y12 inhibitor interaction: potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction","volume":"217","author":"Fernando","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4292\/wjgpt.v6.i2.17","article-title":"Clinical relevance of clopidogrel-proton pump inhibitors interaction","volume":"6","author":"Bouziana","year":"2015","journal-title":"WJGPT"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib109","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/bja\/aeq003","article-title":"To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial","volume":"104","author":"Oscarsson","year":"2010","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.archger.2007.11.003","article-title":"Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction","volume":"48","author":"Feringa","year":"2009","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib111","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: american society of regional anesthesia and pain medicine evidence-based guidelines (Fourth Edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"issue":"5","key":"10.1016\/j.yasu.2025.05.003_bib112","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.athoracsur.2012.07.086","article-title":"Update to the Society of Thoracic Surgeons Guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations","volume":"94","author":"Ferraris","year":"2012","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.yasu.2025.05.003_bib113","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jvs.2023.01.018","article-title":"A framework for perioperative care for lower extremity vascular bypasses: a consensus statement by the enhanced recovery after surgery (ERAS\u00ae) society and society for vascular surgery","volume":"77","author":"McGinigle","year":"2023","journal-title":"J Vasc Surg"},{"issue":"35","key":"10.1016\/j.yasu.2025.05.003_bib114","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu285","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"issue":"7329","key":"10.1016\/j.yasu.2025.05.003_bib115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.yasu.2025.05.003_bib116","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5694\/j.1326-5377.2003.tb05361.x","article-title":"Antiplatelet drugs","volume":"178","author":"Hankey","year":"2003","journal-title":"Med J Aust"},{"issue":"10","key":"10.1016\/j.yasu.2025.05.003_bib117","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jacc.2024.06.027","article-title":"Antithrombotic strategies for patients with peripheral artery disease","volume":"84","author":"Bonaca","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib118","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.05.003_bib119","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib121","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/ATVBAHA.122.318902","article-title":"Gene therapeutic strategies for peripheral artery disease and new opportunities provided by adeno-associated virus vectors","volume":"43","author":"Khachigian","year":"2023","journal-title":"ATVB"},{"key":"10.1016\/j.yasu.2025.05.003_bib122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coph.2018.01.005","article-title":"Cell therapy for peripheral artery disease","volume":"39","author":"Frangogiannis","year":"2018","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.yasu.2025.05.003_bib123","doi-asserted-by":"crossref","first-page":"259","DOI":"10.34172\/apb.2023.025","article-title":"Current and novel emerging medical therapies for peripheral artery disease: a literature review","volume":"13","author":"Arabzadeh","year":"2023","journal-title":"Adv Pharmaceut Bull"},{"issue":"8","key":"10.1016\/j.yasu.2025.05.003_bib124","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00228-022-03346-7","article-title":"Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review","volume":"78","author":"Huang","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"17","key":"10.1016\/j.yasu.2025.05.003_bib125","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for Oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.yasu.2025.05.003_bib126","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American heart association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation (New York, N Y)"},{"issue":"19","key":"10.1016\/j.yasu.2025.05.003_bib127","first-page":"2145","article-title":"Is there a role for preoperative platelet function testing in patients undergoing cardiac surgery during antiplatelet therapy?","volume":"138","author":"Mahla","year":"2018","journal-title":"Circulation (New York, N Y)"},{"issue":"1","key":"10.1016\/j.yasu.2025.05.003_bib131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor\u2019s choice -- European society for vascular surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"}],"container-title":["Advances in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341125000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341125000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:08:49Z","timestamp":1754431729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065341125000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0065341125000168"],"URL":"https:\/\/doi.org\/10.1016\/j.yasu.2025.05.003","relation":{},"ISSN":["0065-3411"],"issn-type":[{"type":"print","value":"0065-3411"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Anticoagulant Management for Peripheral Vascular Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yasu.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}